Catalent helps to advance new opioid addiction treatment

11 Dec 2019

The fast-dispersing Zydis formulation could increase compliance with Medication-Assisted Treatment and thus better clinical outcomes.

Catalent has completed clinical production of Bridge Therapeutics' opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology.

Catalent helps to advance new opioid addiction treatment

Bridge currently intends to seek approval from the FDA for BT-219 under the “505(b)(2)” regulatory submission pathway as well as a possible future single entity buprenorphine product.

Catalent’s Zydis ODT technology is a unique, freeze-dried tablet that disperses almost instantly in the mouth without water. Zydis is recognized as one of the world’s best performing ODTs and has well-established advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience. Bridge’s exclusive license of the Zydis technology will initially apply to the US, with the potential to expand to other nations.

BT-219, or Bunalz, is an investigational new drug (IND) which applies the Zydis delivery technology to buprenorphine and naloxone, which are the active ingredients in the Suboxone prescription medication for opioid addiction. Buprenorphine, being a Schedule III medication, is considered safer and less addictive than methadone, which is classified as a Schedule II medication. It has also been shown that buprenorphine is six-times safer than methadone with regard to overdose risk among the general population.

“Catalent has a proven track record in working with partners to bring new therapies to market quickly and we look forward to working with Bridge as they pursue approval for this important and exciting new development product,” commented Jonathan Arnold, President of Catalent’s Oral and Specialty Delivery business unit. He added, “The Zydis technology platform has been shown to be very versatile and effective in developing easy-to-administer dose forms for innovators and to date, more than 36 products have been launched using Zydis technology in over 60 countries.”

Dr Greg Sullivan, Chief Medical Officer of Bridge Therapeutics, continued: “This new formulation will provide improved administration characteristics. With many formulations being unpleasant to patients, this fast-dispersing Zydis formulation could potentially increase compliance with Medication-Assisted Treatment (MAT) and thus better clinical outcomes”. He added, “In addition to assisting the needs of the general population, utilizing the Zydis formulation technology lessens the chance of an institutionalized patient being able to divert the medication for untoward purposes.”

Read More

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Catalent launches direct-to-patient clinical supply services

Catalent launches direct-to-patient clinical supply services

14 Jan 2020

Multiple options provide increased flexibility for sponsors.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Lupin could face FDA regulatory action over Tarapur API facility

Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more